Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) CFO Fawwad Qureshi sold 828 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $45.53, for a total transaction of $37,698.84. Following the completion of the sale, the chief financial officer now owns 6,079 shares in the company, valued at $276,776.87. This represents a 11.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Trupanion Price Performance
Shares of NASDAQ:TRUP opened at $48.15 on Friday. The company has a market cap of $2.06 billion, a P/E ratio of -209.35, a P/E/G ratio of 6.02 and a beta of 1.72. The business has a fifty day simple moving average of $39.72 and a 200-day simple moving average of $43.96. Trupanion, Inc. has a 52 week low of $25.90 and a 52 week high of $57.90. The company has a quick ratio of 1.66, a current ratio of 1.71 and a debt-to-equity ratio of 0.39.
Trupanion (NASDAQ:TRUP – Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The financial services provider reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The firm had revenue of $341.98 million for the quarter, compared to analyst estimates of $337.81 million. Trupanion had a negative return on equity of 3.08% and a negative net margin of 0.75%. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. During the same period last year, the company earned ($0.16) EPS. Equities research analysts forecast that Trupanion, Inc. will post 0.13 EPS for the current year.
Institutional Investors Weigh In On Trupanion
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the company. Piper Sandler reduced their target price on Trupanion from $57.00 to $52.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Stifel Nicolaus reduced their price objective on Trupanion from $44.00 to $41.00 and set a “hold” rating on the stock in a research report on Thursday, February 20th. Finally, Lake Street Capital dropped their price objective on Trupanion from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Trupanion has a consensus rating of “Moderate Buy” and an average target price of $51.80.
View Our Latest Research Report on TRUP
About Trupanion
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
Featured Articles
- Five stocks we like better than Trupanion
- What is a support level?
- e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal
- How to Choose Top Rated Stocks
- Apple Stock Could Rally After Tariffs Are Blocked By Court
- Industrial Products Stocks Investing
- Archer Aviation Stock Steadies After Short-Seller Report
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.